Lantheus (NASDAQ:LNTH) Stock Price Expected to Rise, Truist Financial Analyst Says

Lantheus (NASDAQ:LNTH) had its price target boosted by analysts at Truist Financial from $120.00 to $127.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s price objective would suggest a potential upside of 35.37% from the company’s current price.

LNTH has been the topic of a number of other reports. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Stock Up 2.5 %

Shares of NASDAQ LNTH opened at $93.82 on Thursday. The stock has a market capitalization of $6.52 billion, a PE ratio of 15.61 and a beta of 0.44. The firm has a fifty day moving average of $89.80 and a 200-day moving average of $96.75. Lantheus has a 52-week low of $56.44 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities research analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC bought a new stake in shares of Lantheus in the third quarter worth $1,066,000. Massachusetts Financial Services Co. MA acquired a new stake in Lantheus in the third quarter valued at $25,955,000. Van ECK Associates Corp raised its holdings in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.